Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1995;92:562-578

This Article
Right arrow Abstract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spinale, F. G.
Right arrow Articles by Koster, W. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spinale, F. G.
Right arrow Articles by Koster, W. H.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Cardiomyopathy

(Circulation. 1995;92:562-578.)
© 1995 American Heart Association, Inc.


Articles

Angiotensin-Converting Enzyme Inhibition and the Progression of Congestive Cardiomyopathy

Effects on Left Ventricular and Myocyte Structure and Function

Francis G. Spinale, MD, PhD; Henry H. Holzgrefe, BS; Rupak Mukherjee, MS; R. Barry Hird, MD; Jennifer D. Walker, MD; Alice Arnim-Barker, BS; James R. Powell, PhD; William H. Koster, PhD

From the Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, and Bristol Myers Squibb Research Institute, Princeton, NJ (H.H.H., J.R.P., W.H.K.).

Correspondence to Francis G. Spinale, MD, PhD, Division of Cardiothoracic Surgery, Room 418 CSB, 171 Ashley Ave, Medical University of South Carolina, Charleston, SC 29425.


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Background Clinical trials have demonstrated that angiotensin-converting enzyme inhibition (ACEI) improves survival in patients with long-term left ventricular (LV) dysfunction. However, it remained unclear from these clinical reports whether the beneficial effects of ACEI were due to direct improvements in LV myocardial structure and function. Accordingly, the overall objective of the present study was to examine the direct effects of ACEI on both LV and myocyte structure and function in the setting of cardiomyopathic disease.

Methods and Results LV and isolated myocyte function and structure were examined in control dogs (n=6), in dogs after the development of dilated cardiomyopathy caused by rapid ventricular pacing (RVP, 216 beats per minute, 4 weeks, n=6), and in dogs with RVP and concomitant ACEI (RVP/ACEI, fosinopril 30 mg/kg BID, n=6). LV ejection fraction fell with RVP compared with control values (35±3 versus 73±2%, P<.05) and was higher with RVP/ACEI compared with RVP values (41±4%, P=.048). LV end-diastolic volume increased with RVP compared with control values (78±7 versus 101±7 cm3, P<.05) and was lower with RVP/ACEI (82±3 cm3, P<.05). Isolated myocyte length increased with RVP (182±1 versus 149±1 µm), and the velocity of shortening decreased (36±1 versus 57±1 µm/s) compared with control values (P<.05). With RVP/ACEI, myocyte length was reduced (169±1 µm) and velocity of shortening was increased (45±1 µm/s) compared with RVP values (P<.05). Myocyte velocity of shortening after ß-adrenergic receptor stimulation with 25 nmol/L isoproterenol was reduced with RVP compared with control values (142±5 versus 193±8 µm/s, P<.05) and significantly improved with RVP/ACEI (166±6 µm/s, P<.05). In the RVP group, ß-adrenergic receptor density fell 26%, and cAMP production with ß-adrenergic receptor stimulation was reduced 48% from control values. RVP/ACEI resulted in a normalization of ß-adrenergic receptor density and cAMP production. LV myosin heavy-chain content when normalized to dry weight of myocardium was unchanged with RVP (149±11 mg per gram dry weight of myocardium [gdwt]) and RVP/ACEI (150±4 mg/gdwt) compared with control values (165±4 mg/gdwt). LV collagen content decreased with RVP compared with control values (7.6±0.4 versus 9.6±0.8 mg per gram wet weight of myocardium [gwwt], P<.05) but was increased with RVP/ACEI (14.4±1.3 mg/gwwt, P<.05).

Conclusions Concomitant ACEI with chronic tachycardia reduced LV chamber dilation and improved myocyte contractile function and ß-adrenergic responsiveness. Contributory cellular and extracellular mechanisms for the beneficial effects of ACEI in this model of dilated cardiomyopathy included a normalization of ß-adrenergic receptor function and enhanced myocardial collagen support. The results from this study provide evidence that ACEI during the development of cardiomyopathic disease provided beneficial effects on LV myocyte contractile processes and myocardial structure.


Key Words: cardiomyopathy • contractility • myosin • angiotensin


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
A major focus of cardiovascular research efforts has been to understand the basic mechanisms underlying the development and progression of congestive heart failure. An important etiology of congestive heart failure is dilated cardiomyopathy.1 In patients with progressive left ventricular (LV) dysfunction, significant activation of neurohormonal systems occurs.2 Clinical studies reported that angiotensin-converting enzyme (ACE) inhibition improved indexes of LV function and survival in patients with cardiomyopathic disease.3 4 5 However, it remained unclear from these clinical studies whether the mechanisms of action of ACE inhibitors were due to global hemodynamic and neurohormonal effects (systemic effects) or whether ACE inhibition directly improved myocardial structure and function (myocardial effects).6 Thus, while it has been demonstrated that survival of patients with symptomatic cardiomyopathic disease has improved with concomitant ACE inhibition, the mechanisms of action have not been clearly established. Furthermore, it is unknown whether ACE inhibition may alter the progression of the cardiomyopathic disease process. Accordingly, one objective of the present study was to examine the direct effects of ACE inhibition on both LV and myocyte structure and function in the setting of cardiomyopathic disease.

Past reports from this laboratory and others demonstrated that chronic tachycardia in animals causes a dilated cardiomyopathy with alterations in LV contractile function, myocardial structure, and sarcolemmal transduction systems.7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Specifically, this laboratory demonstrated that chronic pacing-induced tachycardia caused a reduction in myocyte contractile function and alterations in cytoarchitecture.19 20 21 In addition, past studies have reported that the development of tachycardia-induced cardiomyopathy is associated with a reduction in ß-adrenergic receptor density, diminished cAMP production, and blunted responsiveness to ß-adrenergic receptor stimulation.8 18 23 Thus, this model of dilated cardiomyopathy produces abnormalities in LV function and sarcolemmal transduction systems that are similar to those reported in patients with cardiomyopathic disease.2 6 26 Accordingly, this model of dilated cardiomyopathy was used to test the central hypothesis that concomitant ACE inhibition with chronic tachycardia will have direct effects on LV and myocyte structure and function.


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Experimental Model of Cardiomyopathy
Eighteen adult mongrel dogs of either sex (9 to 16 months of age, 15 to 25 kg; Hazelton) were used in this study. The animals were chronically instrumented to serially measure LV and arterial pressures and to obtain plasma samples. In addition, a pacemaker and stimulating electrode were implanted to produce rapid right ventricular pacing. The animals were anesthetized with thiopental (4 mg/kg, Pentothal, Abbot Labs), intubated, and ventilated with nitrous oxide and oxygen (1:3 ratio). A surgical plane of anesthesia was maintained using 1% to 3% isoflurane (Aurthan, Anaquest), and a left thoracotomy was performed. A shielded stimulating electrode was sutured onto the right ventricular outflow tract, connected to a programmable pacemaker modified for programming heart rates up to 300 beats per minute (bpm) (Spectrax 5985, Medtronic, Inc), and buried in a subcutaneous pocket. A previously calibrated microtipped transducer (model p5-X4, Konigsberg Instruments) was placed into the LV chamber through a small incision at the apex. The connection of the LV transducer was tunneled and externalized in the suprascapular region of each animal. The pericardium was left open, the incision was closed, and the pleural space was evacuated of air. Next, the right carotid artery was exposed, and a vascular access port (model GPV, 9F, Access Technologies) was placed in the artery, advanced to the aortic arch, and sutured in place for subsequent arterial blood pressure measurements and blood sampling. The animals were allowed a 14-day recovery period, at which time a chest roentgenogram was obtained, and proper operation of all implanted instrumentation was confirmed. All animals used in this study were treated and cared for in accordance with the NIH "Guide for the Care and Use of Laboratory Animals" (NIH publication 86-23, 1985).

Experimental Design
After the dogs recovered from the surgical procedure, baseline LV pressure and dimensions and arterial pressure were measured, and plasma samples were obtained for each dog (described below). The pacemakers were then activated for rapid ventricular pacing (216±2 bpm), and 1:1 capture was confirmed by ECG. The dogs were then randomly assigned to one of three treatment protocols: ACE inhibition (dogs were administered the ACE inhibitor fosinopril [30 mg/kg, PO-BID] during the pacing period, n=6), rapid pacing only (dogs were given gelatin capsules during the pacing period, n=6), and sham control (these dogs were instrumented and cared for exactly as the other groups except for activation of the pacemaker, n=6). Cardiac auscultation and an ECG were performed frequently during the 28-day pacing protocol to ensure proper operation of the pacemaker and the presence of 1:1 conduction. At weekly intervals, the dogs were brought to the laboratory, and the pacemakers were deactivated. After a 30-minute stabilization period, LV pressures were recorded, and echocardiographic measurements were obtained as described in the following section. To determine changes in neurohormonal status with the progression of tachycardia-induced cardiomyopathy, plasma samples were obtained immediately after the LV function measurements were made. After the LV function studies and plasma collection, the pacemaker was reactivated (except in the sham controls). At the end of the 28-day pacing protocol, the dogs were returned to the laboratory for terminal study as described in the following section.

LV Function Measurements
Indexes of LV systolic and diastolic function were obtained at baseline and at weekly intervals during the 28-day pacing period with simultaneously recorded pressure and echocardiographic measurements previously described by this laboratory.19 25 All measurements were performed in a darkened room with the animal resting quietly in a sling. The arterial access port was punctured with a 22-gauge Huber point needle (Access Technologies) connected to a fluid-filled catheter. Pressures from the fluid-filled aortic catheter were obtained with an externally calibrated transducer (Statham P23ID, Gould). The ECG and pressure waveforms were recorded with a multichannel recorder (TA4000, Gould) and digitized on computer for subsequent analysis at a sampling frequency of 250 Hz (PO-NE-MAH). Two-dimensional (2D) and M-mode echocardiographic studies (ATL Ultramark 7, 3.5-mHz transducer) were used to image the LV from a right parasternal approach. LV volumes and ejection fractions were computed from the 2D and M-mode echocardiographic recordings.27 Peak positive and negative dP/dt and peak systolic wall stress were computed with methods described previously.19 25

Neurohormonal Measurements
To examine the relation between changes in neurohormonal status that accompany changes in LV function with pacing-induced cardiomyopathy, blood samples were drawn at the conclusion of each LV function study. With the animal resting quietly, 35 cm3 of blood was drawn from the arterial access port into tubes containing EDTA (1.5 mg/mL), sodium azide (0.2 mg/mL), and aprotinin (1.15 TIU/mL). The blood samples were immediately centrifuged (2000g, 10 minutes, 4°C), and the plasma was decanted into separate tubes, frozen in a dry ice–methanol bath, and stored at -80°C until the time of assay. From these plasma samples, norepinephrine concentration, atrial natriuretic peptide levels, cGMP content, and plasma renin activity were determined. Plasma norepinephrine was measured with high-performance liquid chromatography and normalized to picograms per milliliter of plasma.28 For the atrial natriuretic peptide and cGMP assays, the plasma was first eluted over a cation exchange column (C-18 Sep-Pak, Waters Associates). Standardized radioimmunoassay procedures were performed to determine atrial natriuretic peptide concentrations, cGMP levels, and plasma renin activity (Peninsula Laboratories). All assays were shown to have a linear response by use of known standards with <10% coefficient of variation. All plasma assays were performed in duplicate.

Terminal Study: Myocardial Sampling and Myocyte Isolation
Four weeks after institution of the protocols described above, the dogs were brought to the laboratory, and a final series of LV function measurements and plasma samples was obtained. The animals were then anesthetized as described, sternotomies were performed, and the hearts were quickly extirpated and placed in a phosphate-buffered ice slush. The great vessels, atria, and right ventricle were carefully trimmed away, and the LV was weighed. The region of the LV free wall incorporating the circumflex artery (5x5 cm) was excised and prepared for myocyte isolation. The region of the left ventricular free wall comprising the left anterior descending artery (3x5 cm) was cannulated and prepared for perfusion fixation. The posterior region of the LV free wall (3x3 cm) was snap-frozen in liquid nitrogen for subsequent biochemical analysis.

Myocytes were isolated from the LV free wall with methods described by this laboratory previously.19 20 21 Briefly, the left circumflex coronary artery was perfused with a collagenase solution (0.5 mg/mL, Worthington type II; 146 U/mg) for 35 minutes. The tissue was then minced into 2-mm sections and gently agitated. After 15 minutes, the supernatant was removed and filtered, and the cells were allowed to settle. The myocyte pellet was then resuspended in Dulbecco's modified Eagle's medium:nutrient mixture F-12 (GIBCO Laboratories). The number of viable myocytes was counted at x100 magnification with a hemocytometer (Reichert-Jung, Cambridge Instruments Inc) and resuspended to a final concentration of 5x104 cells/mL. Viable myocytes were defined as those cells maintaining a rod shape that were quiescent in culture. With this myocyte isolation method, a high yield (70±8%) of viable myocytes was routinely obtained for the myocyte contractile function measurements as described in a following section.

Myocardial Structural Analysis
The LV section for microscopic analysis was perfused with a buffered sodium cacodylate solution containing 2% paraformaldehyde, 2% glutaraldehyde solution (pH 7.4, 325 milliosmoles per liter) for 20 minutes with a perfusion pressure of 100 mm Hg.19 After perfusion, a 2x2 cm region was finely minced, placed in additional fixative for 3 hours, and then prepared for electron microscopy.19 Six tissue blocks in the circumferential orientation from the LV of each dog were used to obtain thin sections for electron microscopy. Three grids, each containing three thin sections, were prepared from each block. Thin sections were stained with uranyl acetate and lead citrate and examined with a JOEL 100S electron microscope. The central portion of each section was photographed at a calibrated magnification of x10 000. These electron micrographs were then coded, and this code was not broken until completion of the study. From the circumferentially oriented micrographs, the percent volume of myofibrils within myocytes was analyzed morphometrically by use of a stereology sampling grid consisting of 140 sampling points. LV myocardial samples were also examined by scanning electron microscopy. Perfusion-fixed LV myocardial samples were flash-frozen in liquid nitrogen and freeze-fractured.22 The freeze-fractured samples (0.25x0.25 cm) were then dehydrated, and the samples were critical-point dried (Ladd Research Inc). The samples were mounted on 10x10-mm stubs with conductive adhesive tape (Scotch commercial tape, 3M Inc) and coated with gold sputter (Hummer II, Technics). The sections were examined in a JOEL JSM-25S SEM at an accelerating voltage of 15 kV.

Light microscopic examination was performed on the perfusion-fixed LV myocardium to determine myocyte cross-sectional area, percent area occupied by extracellular space, and connectivity of the extracellular network.22 For examination of the extracellular matrix, LV sections were stained with a silver impregnation method.29 The silver-stained LV sections were then digitized at a final magnification of x320 and analyzed with an image analysis system (Zeiss/Kontron, IBAS).22 The percent area of extracellular staining was computed from 15 random fields within the midmyocardium to exclude large epicardial arteries and veins and any cutting or compression artifact. The integrity or continuity of the collagen network was examined in these same fields by use of a grid pattern of 100-µm horizontal and vertical lines. The percent of collagen profiles intersecting this grid was then computed.22 For determination of myocyte cross-sectional area, LV samples previously embedded in resin were sectioned and stained with toluidine blue. These sections were imaged with an epifluorescent illuminator using a rhodamine filter at a magnification of x1000. Myocytes in a cross-sectional orientation were digitized and analyzed with the previously described image analysis system. Only those myocytes in which the nucleus was centrally located within the cell were digitized and analyzed to ensure that the short axis of the cardiocyte was perpendicular to the microscope objective. With this approach, myocyte cross-sectional area could be determined in situ.

Myocardial Biochemical Analysis
To examine the potential changes in myocardial composition that may have occurred with concomitant ACE inhibition with chronic tachycardia, total myocardial protein, water content, myosin heavy-chain (MHC) content, and hydroxyproline content were determined. For total myocardial protein and MHC content, myocardial samples (1 g) were homogenized in a 62.5 mmol/L Tris-HCl buffer (1:10 wt/vol) with a tissue grinder (Tissumizer, Tekmar Co). The homogenate was placed in a vortex and diluted into serial dilutions ranging from 1:100 to 1:1000, and the protein content was determined with a standardized colorimetric assay (Bio-Rad Protein Assay, Bio-Rad Laboratories). The MHC content was determined in these myocardial homogenates with SDS-PAGE.30 An aliquot of the myocardial homogenate (5 µg total protein) was suspended in a buffer containing 125 mmol/L Tris-HCl, 4% SDS, 20% glycerol, 10% ß-mercaptoethanol, and 0.1% bromphenol blue. The samples were boiled for 5 minutes and then immediately loaded onto a vertical maxigel apparatus (Protean II, Bio-Rad Laboratories). The samples were initially separated with a 4% stacking gel and then were resolved with a 10% to 13% gradient with a constant current and voltage set at 70 mV. The gels were run for 17 hours with a constant temperature of 12°C to 15°C maintained. The gels were stained for 3 hours in a 0.3% Coomassie blue R-250 solution and destained for an additional 3 hours. The stained gels were then scanned and digitized with the previously described image analysis system and subjected to 2D densitometric analysis. After digital subtraction of background density, the integrated optical densities (IODs) of the bands corresponding to MHC were computed. The IOD values obtained from the 2D quantification were then transformed to microgram values with purified porcine cardiac MHC standards (1 to 6 µg, Sigma Chemical Co) that had been simultaneously electrophoresed on each gel. All experiments were performed in duplicate.

To determine whether myocardial collagen content changed with chronic tachycardia or concomitant ACE inhibition, a biochemical assay for hydroxyproline, an amino acid specific for collagen, was performed on LV samples with methods described previously.31 Briefly, the LV sections were weighed, lyophilized, and reweighed. The sections were then hydrolyzed and measured spectrophotometrically (550 nm) after reaction with Ehrlich's reagent.31 A conversion factor of 7.46 was used to convert the final hydroxyproline values to total collagen values. All measurements were performed in duplicate.

In light of the fact that abnormalities in ß-adrenergic receptor density and transduction have been reported with the development of tachycardia-induced cardiomyopathy,8 18 23 the present study examined ß-receptor density and cAMP production with the development of tachycardia-induced cardiomyopathy and concomitant ACE inhibition during the development of tachycardia-induced cardiomyopathy. ß-Adrenergic binding and function experiments were performed with well-described methods.8 18 23 26 Briefly, myocyte membranes were prepared with ultracentrifugation techniques, and ß-adrenergic receptor antagonist binding studies were performed with 10 concentrations (0.02 to 1 nmol/L) of 25 µL [125I]cyanopindolol (74 Bq/mmol, Amersham Corp). A standard Scatchard linear regression analysis was performed on the amount of bound and free ligand, with r2>.90 as the criterion for acceptability of the data. With this analysis, the maximal number of binding sites, Bmax, expressed as femtomoles per milligram of protein, and the equilibrium dissociation constant, Kd (nanomoles per liter), were computed.23 26 As an index of ß-adrenergic receptor system function, adenylate cyclase activity was determined by timed cAMP production in aliquots of 30 to 50 µg/100 µL of membrane preparation with well-described methods.8 23 In addition to determination of basal adenylate cyclase activity, cAMP production was measured in the presence of 10-3 mol/L (-) isoproterenol and 100 µmol/L forskolin. These concentrations of isoproterenol and forskolin were previously shown to cause maximal adenylate cyclase activity in sarcolemmal preparations.23 Reactions were terminated by placement of the tubes in boiling water and centrifugation at 6500g for 5 minutes. The cAMP content of the supernatant was determined with a competitive radiolabeled assay (Cyclic AMP 125I RIA, Advanced Magnetics Inc). Results were expressed as picomoles of cAMP produced per milligram of sarcolemmal protein per minute. All measurements were performed in duplicate.

Myocyte Contractile Function Measurements
Isolated myocytes were placed in a thermostatically controlled chamber (37°C) fitted with a coverslip on the bottom for imaging on an inverted microscope (Axiovert IM35, Zeiss Inc). The 2.5-mL chamber contained two stimulating platinum electrodes. The myocytes were imaged with an X20 long-working-distance Hoffmann Modulation Contrast objective (Modulation Optics Inc). Myocyte contractions were elicited by field stimulating the tissue chamber at 1 Hz (S11, Grass Instruments) with 5-millisecond current pulses and voltages 10% above the contraction threshold. The polarity of the stimulating electrodes was alternated at every pulse to prevent buildup of electrochemical by-products. Myocyte contractions were imaged using a charge-coupled device with a noninterlaced scan rate of 240 Hz (GPCD60, Panasonic). Myocyte motion signals were captured with the cell parallel to the video raster lines, and this video signal was input through an edge detector system (Crescent Electronics). The changes in light intensity at the myocyte edges were used to track myocyte motion.21 The distances between the left and right myocyte edges were converted into a voltage signal, digitized, and input into a computer (80286, ZBV2526, Zenith Data Systems) for subsequent analysis. Stimulated myocytes were allowed a 5-minute stabilization period, after which contraction data for each myocyte were recorded from a minimum of 20 consecutive contractions. Parameters computed from the digitized contraction profiles included percentage shortening (percent), peak velocity of shortening (micrometers per second), peak velocity of relengthening (micrometers per second), total contraction duration (milliseconds), and time to peak contraction (milliseconds). After collection of baseline indexes of myocyte function, measurements were performed in the presence of 25 nmol/L (-) isoproterenol. This concentration of isoproterenol was previously shown to produce a maximal contractile response in isolated myocyte preparations.23 32

Data Analysis
Indexes of LV function, myocardial biochemical composition, and isolated myocyte function were compared among the three groups by ANOVA. The morphological data were analyzed by use of the average measurements obtained for each animal, and the groups were compared by ANOVA. If the ANOVA revealed significant differences, pairwise tests of individual group means were compared by use of Bonferroni probabilities.33 For comparisons of neurohormonal profiles between groups, the Mann-Whitney rank-sum test was used.33 All statistical procedures were performed using the BMDP statistical software package (BMDP Statistical Software Inc). Results are presented as mean±SEM. Values of P<.05 were considered to be statistically significant.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
In the present study, six dogs were successfully studied in each of the following treatment groups: (1) dogs undergoing 28 days of rapid ventricular pacing and concomitant ACE inhibition, (2) dogs undergoing 28 days of rapid pacing with no drugs (gelatin capsule only), and (3) sham-operated controls (no pacing or drug administration). Myocytes were successfully harvested from all animals at the end of the study with no differences in the yield of viable myocytes between groups (P>.75).

LV Function With Chronic Rapid Pacing: Effects of ACE Inhibition
Fig 1Down shows the weekly changes in LV end-diastolic pressure, volume, and ejection fraction with long-term rapid pacing. LV end-diastolic pressure and volume significantly increased after 1 week of pacing compared with sham controls (P<.05) and increased in a time-dependent fashion with each week of rapid pacing. In the rapid pacing group, LV ejection fraction decreased significantly from baseline values and from sham control values after 1 week of pacing (P<.05) and continued to decline with each week of rapid ventricular pacing. Thus, consistent with past reports from this laboratory and others, chronic pacing-induced tachycardia caused LV dilation and pump dysfunction.7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 In dogs receiving concomitant ACE inhibition during chronic tachycardia, there was no significant change in LV end-diastolic pressure or volume after 1 week of rapid pacing compared with baseline values or sham controls (Fig 1Down). There was no difference in LV end-diastolic pressures between the group receiving rapid pacing only and the group undergoing concomitant ACE inhibition. After 2 weeks of rapid pacing, LV end-diastolic volume increased from baseline values in the group undergoing concomitant ACE inhibition but remained significantly lower than values in the group undergoing rapid pacing alone for the entire pacing protocol (P<.05). After 1 week of pacing, LV ejection fraction was significantly lower in the group undergoing ACE inhibition and rapid pacing compared with baseline values or sham controls (P<.05) and declined with each week of pacing. After 4 weeks of rapid pacing, LV ejection fraction was higher in the group undergoing ACE inhibition compared with the value in the group undergoing rapid pacing alone (P=.048). Thus, concomitant ACE inhibition significantly reduced the progressive LV dilation associated with chronic pacing tachycardia and improved LV pump function.



View larger version (16K):
[in this window]
[in a new window]
 
Figure 1. Graphs showing weekly changes in left ventricular end-diastolic pressure (LVEDP), end-diastolic volume, and ejection fraction in control dogs ({blacktriangledown}), dogs with long-term rapid pacing ({blacktriangleup}), and dogs with long-term pacing and concomitant angiotensin-converting enzyme (ACE) inhibition ({bullet}). Top, Long-term rapid pacing resulted in a significant increase in LVEDP by week 1 compared with controls (P<.05) and increased with each week of rapid pacing. In contrast, concomitant ACE inhibition resulted in lower LVEDP during weeks 1 through 3 compared with untreated dogs undergoing rapid pacing (P<.05). However, by week 4, LVEDP was equivalent in both rapid pacing groups. Middle, LV end-diastolic volume significantly increased with each week of rapid pacing and appeared to plateau by week 4. LV end-diastolic volume was significantly lower in the rapid pacing and concomitant ACE inhibition group at all time points compared with the group receiving only rapid pacing (P<.05). Bottom, LV ejection fraction fell in a time-dependent manner with each week of pacing regardless of drug treatment (P<.05). However, at weeks 3 and 4, a higher LV ejection fraction was observed in the rapid pacing and ACE inhibition group compared with the group receiving rapid pacing alone (P<.05). See Table 1Up for week 4 summary results.

To more carefully examine the relation between changes in LV loading conditions and LV geometry with long-term rapid pacing and with concomitant ACE inhibition, peak LV wall stress was computed at each week of the pacing protocol (Fig 2Down). LV peak wall stress significantly increased with each week of rapid pacing compared with the sham control group (P>.05). In the group undergoing ACE inhibitor and rapid pacing, LV wall stress was not significantly different from baseline or sham control values after 1 week of pacing (P=.417). In this group,, LV peak wall stress remained significantly lower compared with the value in the group undergoing rapid pacing only for the entire pacing protocol (P<.05). Thus, the significant reduction in LV chamber size with concomitant ACE inhibition was associated with significantly reduced LV peak wall stress.



View larger version (14K):
[in this window]
[in a new window]
 
Figure 2. Graph showing weekly changes in left ventricular (LV) peak wall stress in control dogs ({blacktriangledown}), dogs with long-term rapid pacing ({blacktriangleup}), and dogs with long-term pacing and concomitant angiotensin-converting enzyme (ACE) inhibition ({bullet}). In untreated dogs, LV wall stress increased significantly with each week of pacing (P<.05). In contrast, a significant reduction in LV wall stress was observed with concomitant ACE inhibition at weeks 2 through 4 of long-term rapid pacing (P<.05). See Table 1Up for week 4 summary results.

Table 1Down summarizes the LV function and hemodynamics obtained in sham controls and after 28 days of rapid pacing and 28 days of rapid pacing with concomitant ACE inhibition. Resting heart rate was increased and mean arterial pressure was reduced in the group receiving rapid pacing only compared with sham controls. Similarly, concomitant ACE inhibition caused a significant reduction in mean arterial pressure compared with sham controls but was not significantly different from the value in the group undergoing rapid pacing only (P=.261). After 4 weeks of rapid pacing, LV peak systolic pressure and peak +dP/dt were significantly lower with rapid pacing compared with the control group, regardless of ACE inhibition. As outlined in Fig 1Up and presented in Table 1Down, the significant LV dilation that occurred with long-term rapid pacing was ameliorated with concomitant ACE inhibition.


View this table:
[in this window]
[in a new window]
 
Table 1. Changes in LV Function With Pacing-Induced Cardiomyopathy: Effects of ACE Inhibition

Neurohormonal Changes With Chronic Rapid Pacing and Concomitant ACE Inhibition
Fig 3Down shows a summary of weekly changes in plasma norepinephrine, atrial natriuretic factor (ANF), and cGMP. Plasma norepinephrine significantly increased from baseline values after 1 week in the groups undergoing rapid pacing only and undergoing rapid pacing with concomitant ACE inhibition. However, these 1-week plasma norepinephrine values were lower in the group undergoing ACE inhibitor compared with the values in the group undergoing rapid pacing only (P<.05). With longer durations of pacing, plasma norepinephrine values appeared to plateau but remained significantly elevated from baseline values. In the group receiving ACE inhibition with longer durations of pacing, plasma norepinephrine remained higher than baseline values but was consistently lower than the values in the group undergoing rapid pacing only (P<.05). After 1 week of rapid pacing, plasma ANF and cGMP concentrations significantly increased from baseline values and remained elevated throughout the pacing protocol. With rapid pacing and concomitant ACE inhibition, plasma ANF was increased from control values after 1 and 2 weeks of pacing but remained significantly lower than values in the group undergoing rapid pacing only (P<.05). With rapid pacing and concomitant ACE inhibition, cGMP was not increased from baseline values. In the group undergoing rapid pacing only, plasma renin activity remained unchanged from sham control values after 28 days of rapid pacing (3.2±0.9 versus 3.1±0.9 ng · mL-1 · h-1, respectively). With rapid pacing and concomitant ACE inhibition, plasma renin activity was significantly higher than in the sham control group and the group undergoing rapid pacing only (6.9±1.6 ng · mL-1 · h-1, P<.05). The significant increase in plasma renin activity with chronic ACE inhibition is an expected pharmacological effect of interruption of the renin-angiotensin system.12 34 Thus, concomitant ACE inhibition caused a significant reduction in the degree of neurohormonal activation associated with chronic tachycardia.



View larger version (15K):
[in this window]
[in a new window]
 
Figure 3. Graphs show serial changes in plasma norepinephrine, atrial natriuretic factor (ANF), and cGMP in control dogs ({blacktriangledown}), dogs with long-term rapid pacing ({blacktriangleup}), and dogs with long-term pacing and concomitant ACE inhibition ({bullet}). Top, Plasma norepinephrine significantly increased from baseline values in the group receiving rapid pacing only and the group receiving rapid pacing and ACE inhibition group after 1 week of rapid pacing (P<.05). In both rapid pacing groups, plasma norepinephrine appeared to plateau with longer durations of long-term tachycardia. Plasma norepinephrine concentrations were significantly lower with angiotensin-converting enzyme (ACE) inhibition compared with values from the rapid pacing only group (P<.05). Middle, Plasma levels of ANF were significantly increased after 1 week of rapid pacing (P<.05) and remained elevated for the entire 4-week pacing protocol. In the rapid pacing and ACE inhibition group, plasma ANF was increased from control values after 1 and 2 weeks of pacing (P<.05). Bottom, Plasma cGMP levels increased after 1 week of long-term rapid pacing (P<.05) and remained elevated for the remainder of the rapid pacing protocol. In contrast, there was no significant increase in baseline plasma cGMP levels with long-term rapid pacing and concomitant ACE inhibition (P>.50).

LV Structure With Rapid Pacing: Effects of ACE Inhibition
Table 2Down summarizes the LV mass obtained at autopsy and myocardial composition for the three groups of dogs. There was no significant change in LV mass in the group undergoing long-term rapid pacing compared with the sham control group. Absolute LV mass was lower in the group with rapid pacing and concomitant ACE inhibition compared with that of the sham control group (P=.025). Body weight was lower in the dogs with chronic ACE inhibition, but this difference did not reach statistical significance (P>.10). The ratios of LV mass to body weight obtained in the present study for the control group and the groups undergoing rapid pacing are all within normal limits for dogs of this size and were not significantly different between groups.35 When LV mass was normalized to tibial length, the ratio of LV mass to tibial length was lower in the group undergoing rapid pacing and ACE inhibitor compared with the sham control group (P=.041). Thus, as previously reported by this laboratory and others,7 9 18 19 20 21 22 23 25 the development of tachycardia-induced cardiomyopathy was not associated with LV hypertrophy. Concomitant ACE inhibition caused a small but statistically significant reduction in LV mass.


View this table:
[in this window]
[in a new window]
 
Table 2. Changes in LV Mass, Composition, and Morphometry With Pacing-Induced Cardiomyopathy: Effects of ACE Inhibition

LV myocardial structure and composition were examined by morphometric analysis of perfusion-fixed myocardial sections. Myocyte cross-sectional area was computed from a minimum of 350 myocyte profiles from each group. Table 2Up gives the summary values for this analysis; Fig 4Down shows the frequency distribution for this parameter. Myocyte cross-sectional area decreased from sham control values in the group undergoing rapid pacing. In the group undergoing rapid pacing and concomitant ACE inhibitor, myocyte cross-sectional area was significantly reduced from that of the sham control group and the group undergoing rapid pacing only. Ultrastructural quantification was performed on perfusion-fixed myocardial sections taken from each group with coded electron micrographs. These electron micrographs were examined in a blinded fashion, and the code was not broken until the end of the study. Table 2Up summarizes this analysis, and Fig 5Down shows representative electron micrographs of myocardial sections taken in cross-sectional orientation and longitudinal orientations. Absolute myofibril and mitochondrial volumes did not significantly change from control values in either of the groups undergoing rapid pacing. However, changes in mitochondrial structure and cristae formation were apparent in the groups undergoing rapid pacing compared with the control group (Fig 5Down). In longitudinal orientation, sarcomeric units appeared out of register in adjoining myofibrils in the group receiving rapid pacing compared with the control group. This myofibril misalignment was not as apparent in longitudinal sections taken from the group receiving ACE inhibition and rapid pacing.



View larger version (37K):
[in this window]
[in a new window]
 
Figure 4. Bar graphs showing frequency distribution of myocyte cross-sectional area from left ventricular myocardial sections perfusion fixed in situ: sham controls (A), after 28 days of rapid ventricular pacing (B), and rapid pacing and concomitant angiotensin-converting enzyme (ACE) inhibition (C). Myocyte cross-sectional area values were also fitted to a gaussian distribution and are indicated by solid lines. Long-term rapid pacing resulted in a significant decline in myocyte cross-sectional area compared with control values (P<.05). A further decline from rapid pacing alone values was observed with concomitant ACE inhibition and rapid pacing (P<.05). Table 2Up gives summary statistics for this portion of the study.



View larger version (209K):
[in this window]
[in a new window]
 
Figure 5. Representative electron micrographs of perfusion-fixed left ventricular myocardium taken from control dogs, dogs with long-term rapid pacing, and dogs with lo\/ng-term pacing and concomitant ACE inhibition. Left, sections taken in a cross-sectional orientation; right, sections taken from a longitudinal orientation. In sham controls (1a and 1 b), myofibrils were well organized and mitochondria were equally distributed around the myofibril units. After 28 days of rapid ventricular pacing (2a and 2b), the myofibrils appeared disorganized. In longitudinal sections, 28 days of rapid pacing caused noticeable changes in sarcomere alignment and changes in myofibril orientation within the myocyte. Concomitant angiotensin-converting enzyme inhibition (3a and 3b) did not appear to change relative intracellular structure and composition compared with the group receiving rapid pacing only. Quantitative morphometry was performed on myocardial sections taken from each group and is summarized in Table 2Up. Original magnification: left, x10 000; right, x6000.

To more carefully examine potential changes in myocardial composition with rapid pacing and with concomitant ACE inhibition, biochemical quantification of total myocardial protein and MHC was performed. Table 2Up summarizes these biochemical studies. When expressed in terms of wet weight of myocardium, total myocardial protein was significantly reduced in the group undergoing rapid pacing and the group receiving concomitant ACE inhibition. However, when this value was expressed in terms of dry weight, there were no significant differences in total myocardial protein. Fig 6Down shows a representative SDS-PAGE gel for MHC. A strong positive band for MHC was obtained from all the myocardial samples used in this study, and Table 2Up gives the results from 2D quantification of these gels. When expressed in terms of wet weight of myocardium, MHC content was reduced in the group receiving ACE inhibition and rapid pacing compared with the control group. However, when MHC was expressed in terms of dry weight, there was no significant change in this value in either of the groups undergoing rapid pacing compared with the control group. Thus, while MHC was consistently reduced with rapid pacing, this difference did not achieve statistical significance.



View larger version (64K):
[in this window]
[in a new window]
 
Figure 6. Gradient SDS-PAGE performed on left ventricular myocardial samples taken from control dogs (CON), after 4 weeks of rapid ventricular pacing (RVP), and with concomitant angiotensin-converting enzyme inhibition and rapid pacing (ACE). This representative SDS-PAGE indicates location of bovine serum albumin standard (BSA; molecular weight, 66 000) and myosin heavy-chain standard (MHC; molecular weight, 205 000). The positive MHC bands were digitized and the integrated optical density was transformed to absolute MHC content by use of purified standards. Table 2Up gives summary statistics for each group.

To identify a potential structural basis for the changes in LV geometry with rapid pacing and with concomitant ACE inhibition, extracellular matrix structure and composition were examined (Table 2Up). Morphometric analysis of silver-stained LV myocardial sections revealed a significant reduction in positive staining in the group receiving rapid pacing compared with the control group. Furthermore, the confluent nature of the extracellular space was reduced in the group receiving rapid pacing compared with the controls. Fig 7Down shows representative scanning electron micrographs of control myocardium and myocardial samples taken after 28 days of rapid pacing. In control myocardium, a fine weave of collagen was observed within the interstitial space. With chronic rapid pacing, this collagen weave appeared significantly disrupted, and the fine fibrillar nature of the collagen weave could not be readily appreciated. In the group undergoing ACE inhibition and rapid pacing, the percent area of positive silver staining significantly increased from the group receiving rapid pacing only and the control group. This increased silver staining with concomitant ACE inhibition was accompanied by significantly increased confluence of the extracellular staining pattern. With rapid pacing and concomitant ACE inhibition, scanning electron micrographs revealed a well-developed collagen weave surrounding individual myocytes that was distributed in a meshlike pattern throughout the interstitial space. To more carefully quantify changes in LV myocardial collagen, biochemical analysis of hydroxyproline was performed and converted to collagen values (Table 2Up). A small but significant reduction in total myocardial collagen was observed in the group receiving rapid pacing only compared with the control group (P=.035). In the group receiving concomitant ACE inhibition, myocardial collagen content was significantly increased from the values in the group undergoing rapid pacing only and from control values.



View larger version (213K):
[in this window]
[in a new window]
 
Figure 7. Representative scanning electron micrographs of left ventricular (LV) myocardial sections taken from control dogs (1a and 1b), after 4 weeks of long-term rapid pacing (2a and 2b), and after 4 weeks of long-term rapid pacing with concomitant angiotensin-converting enzyme (ACE) inhibition (3a and 3b). In control myocardium, the collagen matrix could be readily observed to surround individual myocytes in a homogenous and weave-like pattern. After 28 days of rapid ventricular pacing, the collagen weave appeared significantly disrupted with large areas of discontinuity between myocytes. In marked contrast, long-term rapid pacing with ACE inhibition resulted in significantly increased collagen weave surrounding individual myocytes. This collagen weave appeared to be of a fine fibrillar network and was well distributed throughout the interstitial space. Quantitative analysis of silver-stained LV myocardial sections was performed and is summarized in Table 2Up. Original magnification x480.

Sarcolemmal Receptor Systems With Rapid Pacing: Effects of ACE Inhibition
Past reports demonstrated that chronic tachycardia caused alterations in the ß-adrenergic receptor systems.8 18 23 Accordingly, ß-adrenergic receptor density and affinity and cAMP production were examined to determine whether concomitant ACE inhibition during long-term rapid pacing influenced this sarcolemmal transduction system. Table 3Down gives the results from this portion of the study. Consistent with past reports,8 18 23 ß-adrenergic receptor density fell significantly with chronic rapid pacing with no change in affinity. In marked contrast, there was no change in ß-adrenergic receptor density or affinity with concomitant ACE inhibition and long-term rapid pacing. In control sarcolemmal preparations, cAMP production significantly increased from basal levels after ß-adrenergic receptor stimulation with isoproterenol and after direct adenylate cyclase activation with forskolin. Long-term rapid pacing caused a reduction in basal cAMP levels compared with controls. Furthermore, cAMP production with ß-adrenergic receptor stimulation or by direct adenylate cyclase activation was reduced in the group receiving rapid pacing compared with the control group. Concomitant ACE inhibition and rapid pacing resulted in a normalization of cAMP production both after ß-adrenergic receptor stimulation and by direct activation of adenylate cyclase. Thus, concomitant ACE inhibition with long-term rapid pacing maintained ß-receptor density and normalized cAMP production. The direct effects of these changes in ß-receptor density and transduction with chronic rapid pacing and with concomitant ACE inhibition on myocyte ß-adrenergic responsiveness were examined next.


View this table:
[in this window]
[in a new window]
 
Table 3. Changes in the ß-Adrenergic System With Pacing-Induced Cardiomyopathy: Effects of ACE Inhibition

Isolated Myocyte Contractile Function
Table 4Down summarizes the isolated myocyte resting length and contractile function at baseline and after ß-adrenergic stimulation with isoproterenol. Fig 8Down shows representative photomicrographs of isolated myocytes taken from sham controls, from dogs undergoing long-term rapid pacing, and from dogs receiving long-term rapid pacing and concomitant ACE inhibition. Isolated myocyte resting length significantly increased from control values in the group receiving rapid pacing and the group receiving concomitant ACE inhibition. Isolated myocyte length was shorter in the group receiving concomitant ACE inhibition and rapid pacing compared with values in the group undergoing rapid pacing alone. Myocyte percent and velocity of shortening fell significantly from control values in the group undergoing rapid pacing and the group receiving concomitant ACE inhibition. However, in the group receiving rapid pacing and concomitant ACE inhibition, myocyte percent and velocity of shortening were higher than in the group receiving rapid pacing only. The velocity of myocyte lengthening was lower in both groups with long-term rapid pacing. However, in the group receiving concomitant ACE inhibition, the velocity of myocyte lengthening was significantly higher than in the group receiving rapid pacing only. The time to peak myocyte contraction and total duration of contraction were significantly prolonged in the group undergoing rapid pacing without drug treatment. In the group receiving concomitant ACE inhibition, time to peak myocyte contraction returned to control values. Thus, consistent with past reports, long-term pacing-induced tachycardia caused a significant reduction in isolated myocyte contractile function.21 23 Results from the present study demonstrated that chronic pacing-induced tachycardia with concomitant ACE inhibition improved indexes of myocyte contractile function.


View this table:
[in this window]
[in a new window]
 
Table 4. Isolated Myocyte Contractile Performance With Pacing-Induced Cardiomyopathy: Effects of ACE Inhibition



View larger version (29K):
[in this window]
[in a new window]
 
Figure 8. Representative photomicrographs of isolated myocytes taken from sham controls (A), after 28 days of rapid ventricular pacing (B), and after rapid pacing with concomitant angiotensin-converting enzyme (ACE) inhibition (C). Isolated myocyte length significantly increased with long-term rapid pacing. With concomitant ACE inhibition, myocyte length was reduced from rapid pacing alone values. Summary statistics are presented in Table 4Up. Bar=50 µm.

In light of the fact that rapid pacing with concomitant ACE inhibition improved ß-adrenergic receptor density and cAMP production compared with rapid pacing alone, myocyte contractile function was examined in the presence of the ß-adrenergic agonist isoproterenol. ß-Adrenergic receptor stimulation caused a consistent and significant increase in contractile function from baseline values in the control myocytes, in myocytes after 28 days of rapid pacing, and in myocytes with concomitant ACE inhibition. Myocyte contractile function in the presence of isoproterenol was significantly lower than control values in the group undergoing rapid pacing only and the group receiving ACE inhibition. However, ß-adrenergic responsiveness was significantly greater in the group receiving concomitant ACE inhibition compared with the values from the group undergoing rapid pacing only. Thus, the normalization of ß-adrenergic receptor density and transduction with long-term rapid pacing and concomitant ACE inhibition caused a direct improvement in isolated myocyte ß-adrenergic responsiveness.

With long-term rapid pacing, myocyte lengthening velocity significantly fell from control values and increased with concomitant ACE inhibition. Whether these changes in myocyte lengthening rate indicated a change in intrinsic myocyte relaxation properties was not clear because lengthening rate can be changed by an alteration in shortening extent alone.36 To differentiate shortening-dependent changes in lengthening rates from changes in lengthening rates caused by intrinsic alterations in relaxation properties, an additional set of experiments was performed. In these experiments, the relation between the extent of myocyte shortening and the velocity of relengthening was developed as previously described.36 Isolated myocytes were stimulated after a period of quiescence, and the beat-to-beat changes in shortening extent and lengthening velocity for the first 20 beats were computed.36 Sequential contraction profiles were obtained at baseline and in the presence of 25 nmol/L isoproterenol. Table 5Down summarizes the results of the regression analysis for this relation. Fig 9Down shows the regression lines obtained for the relation between the extent of shortening and the velocity of lengthening. The slope of this relation fell significantly from control values in both groups receiving rapid pacing and remained depressed with ß-adrenergic stimulation. In the group undergoing rapid pacing and ACE inhibition, the slope of the relation between the extent of shortening and the velocity of lengthening was significantly higher than that for the group undergoing rapid pacing alone. Thus, results from this analysis suggest that one mechanism for the improved myocyte contractile function observed with ACE inhibition in this model of chronic tachycardia is enhanced myocyte active relaxation properties.


View this table:
[in this window]
[in a new window]
 
Table 5. Myocyte Extent of Shortening and Relengthening Velocity Relation With Pacing-Induced Cardiomyopathy: Effects of ACE Inhibition



View larger version (13K):
[in this window]
[in a new window]
 
Figure 9. Regression lines for the relation between extent of shortening and velocity of relengthening for each group of myocytes studied. Rapid ventricular pacing for 28 days caused a significant fall in the slope of this relation from control values. Rapid pacing and concomitant angiotensin-converting enzyme (ACE) inhibition significantly increased the slope of this relation from the values in the rapid pacing only group (P<.05). These results suggest that ACE inhibition with long-term tachycardia significantly improved isolated myocyte relaxation processes. Table 5Up gives the regression analysis by which these regression lines were developed and the values obtained at baseline and with ß-adrenergic stimulation.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
Cardiomyopathic disease is accompanied by LV dilation and dysfunction with activation of neurohormonal systems.1 2 5 6 26 Recent clinical reports demonstrated improved survival in patients with LV dysfunction treated with ACE inhibitors.3 4 However, the direct effects of ACE inhibition on LV myocardial structure and myocyte contractile processes during the progression of cardiomyopathic disease remain unclear. To address this issue, the present study examined the direct effects of concomitant ACE inhibition during the development of tachycardia-induced cardiomyopathy on LV function and structure and myocyte contractile function and ß-adrenergic responsiveness. The significant and unique findings of this study were fourfold. First, concomitant ACE inhibition reduced the LV dilation that accompanies the development of tachycardia-induced cardiomyopathy. Second, the improved LV geometry with ACE inhibition was associated with a preservation of the LV myocardial collagen matrix. Third, ACE inhibition with chronic tachycardia improved myocyte contractile function and ß-adrenergic responsiveness compared with the group undergoing rapid pacing only. Fourth, the fundamental mechanism for the improved myocyte ß-adrenergic responsiveness with concomitant ACE inhibition during chronic tachycardia was a normalization of ß-adrenergic receptor density and transduction. Thus, results from the present study demonstrated for the first time that ACE inhibition during the development of a cardiomyopathic disease process has direct and beneficial effects on LV myocardial structure and myocyte contractile processes.

It is well established that in animals, 3 to 5 weeks of chronic tachycardia causes a dilated cardiomyopathy.7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Specifically, serial measurements of LV function with chronic tachycardia revealed a progressive increase in LV diastolic volume and an incremental fall in LV ejection fraction with chronic pacing tachycardia.7 11 18 24 In the present study, LV function was serially measured with the progression of tachycardia-induced cardiomyopathy and with concomitant ACE inhibition. Concomitant ACE inhibition with long-term rapid pacing resulted in a significant reduction in LV end-diastolic volume and a small improvement in LV ejection fraction compared with values in dogs undergoing long-term pacing only. The reduced LV end-diastolic volume and increased LV ejection fraction observed after 4 weeks of rapid pacing and concomitant ACE inhibition are probably due to both cellular and extracellular factors. First, long-term ACE inhibition with chronic tachycardia resulted in improved myocyte contractile function. Thus, a contributory mechanism for the increased LV pump function with ACE inhibition and chronic tachycardia is improved myocyte contractile function. Second, ACE inhibition with chronic rapid pacing increased myocardial collagen content. It has been postulated that the fibrillar collagen network of the heart ensures structural integrity of adjoining myocytes, provides the means by which myocyte shortening is translated into overall ventricular pump function, and contributes significantly to the maintenance of LV geometry.37 38 39 In the present study, abnormalities in LV myocardial collagen structure and content were observed with the development of tachycardia-induced cardiomyopathy, and these findings are similar to past reports.22 40 41 Thus, the reduced LV dilation observed with concomitant ACE inhibition during rapid pacing may have been due, at least in part, to increased myocardial collagen content and improved extracellular support. While the present study demonstrated that the reduced LV dilation with rapid pacing and concomitant ACE inhibition was associated with a preservation of collagen content and structure, the effects of these changes on myocardial stiffness properties were not examined. Furthermore, the present study quantified the absolute amount of myocardial collagen content by hydroxyproline assays and did not address whether possible changes in collagen phenotypes occurred with long-term rapid pacing or concomitant ACE inhibition. It was demonstrated that alterations in myocardial collagen content and composition can influence myocardial stiffness properties.42 In addition, long-term ACE inhibition has been demonstrated to directly influence collagen phenotypes.43 In light of the findings of the present study that ACE inhibition influenced collagen content and structure with long-term rapid pacing, future studies of the direct effects of ACE inhibition on myocardial stiffness properties and collagen phenotypes in this model of cardiomyopathic disease would be appropriate.

Concomitant ACE inhibition significantly reduced peak LV myocardial wall stress after 4 weeks of rapid pacing compared with untreated dogs with chronic tachycardia. In light of the fact that there were similar changes in LV peak systolic pressure and wall thickness between the groups receiving rapid pacing alone and undergoing rapid pacing with ACE inhibition, a major contributory factor for the reduction in peak LV wall stress with long-term ACE inhibition was the reduction in LV chamber size. Because LV ejection fraction is dependent on afterload, an additional contributory mechanism for the improved LV ejection fraction with ACE inhibition may have been a reduction in afterload. However, the present study demonstrated that isolated myocyte contractile function, which is independent of systemic loading conditions, was significantly improved with concomitant ACE inhibition with chronic tachycardia. Thus, the beneficial effects of ACE inhibition on LV function in this model of cardiomyopathic disease were twofold. First, ACE inhibition ameliorated the LV dilation that invariably develops with chronic pacing tachycardia7 9 11 18 19 20 21 22 23 25 and thereby reduced LV myocardial wall stress. Second, concomitant ACE inhibition with long-term rapid pacing improved myocyte function and potentially enhanced LV contractile performance.

ANF is a peptide hormone of cardiac origin with multiple biological effects, and cGMP is generated after stimulation of ANF receptors. Thus, circulating levels of cGMP can be used as an index of ANF receptor activation. In the present study, pacing-induced tachycardia caused a significant increase in plasma ANF and cGMP. This is consistent with a number of past reports that demonstrated that the institution of rapid ventricular pacing results in increased atrial pressures with concomitant elevations in plasma ANF.7 12 14 15 16 24 For example, Moe and colleagues14 serially measured neurohormonal profiles in dogs during the development of pacing-induced heart failure and reported a progressive increase in plasma ANF. In the present study, concomitant ACE inhibition with chronic tachycardia resulted in a significant reduction in ANF and cGMP levels compared with those in untreated dogs with chronic tachycardia. This reduction in ANF and cGMP was associated with reduced LV dilation and preservation of sarcolemmal ß-adrenergic receptor density and transduction. Thus, potential mechanisms for this reduction in ANF and cGMP levels with long-term ACE inhibition include reduced activation of atrial stretch receptors, diminished local ANF production resulting from modulation of local neuroendocrine function, and enhanced ANF degradation. However, the specific mechanisms responsible for the significant reduction in plasma ANF and cGMP with rapid pacing and concomitant ACE inhibition remain speculative and were beyond the scope of the present study. Nevertheless, the present study demonstrated that ACE inhibition with rapid pacing significantly attenuated the degree of neurohormonal activation, which has been well established in this model of cardiomyopathic disease.7 8 9 10 12 13 14 15 16 17 18 23 24

Consistent with past reports,8 18 23 44 long-term rapid pacing increased plasma norepinephrine concentrations and was associated with abnormalities in ß-adrenergic receptor density and cAMP production. Similar changes in the ß-adrenergic receptor system have also been reported in patients with cardiomyopathic disease.26 45 In the present study, these abnormalities in the ß-adrenergic receptor system with the development of tachycardia-induced cardiomyopathy were accompanied by reduced myocyte ß-adrenergic responsiveness. More importantly, the present study demonstrated that concomitant ACE inhibition with chronic tachycardia prevented the downregulation of ß-adrenergic receptor density and normalized cAMP production. One proposed mechanism for the changes in the ß-adrenergic receptor system with cardiomyopathic disease is that the elevated circulating catecholamine levels result in long-term ß-receptor activation with subsequent receptor downregulation and alterations in the transduction system.26 While elevated from baseline values, chronic tachycardia with concomitant ACE inhibition reduced plasma catecholamines from values in dogs undergoing rapid pacing only. These results suggest that one mechanism for the preservation of ß-receptor density and the increase in cAMP production with ACE inhibition was a reduction in circulating catecholamines and diminished ß-receptor activation. Bristow et al46 demonstrated that abnormalities in the ß-receptor transduction system can occur as a result of local adrenergic activity within the LV myocardium. In addition, Maisel et al47 demonstrated that long-term ACE inhibition can directly modulate ß-receptor density. Thus, a second potential mechanism for the beneficial effects of ACE inhibition on the ß-adrenergic receptor system with chronic tachycardia includes direct modulation of local cardiac neuroendocrine function. In the present study, the normalization of ß-receptor density and cAMP production with ACE inhibition and chronic tachycardia was associated with increased myocyte ß-adrenergic responsiveness. However, concomitant ACE inhibition with chronic tachycardia did not return myocyte ß-adrenergic responsiveness to control levels. This laboratory and others previously demonstrated that the abnormalities in ß-adrenergic receptor transduction and responsiveness with the development of tachycardia-induced cardiomyopathy were associated with alterations in the guanine nucleotide–binding regulatory protein complex (G-protein complex).18 44 Furthermore, the development of cardiomyopathic disease was demonstrated to cause alterations in ß-adrenergic receptor subtype expression.26 Thus, potential contributory mechanisms for the failure of concomitant ACE inhibition with chronic tachycardia to normalize myocyte ß-adrenergic responsiveness are persistent abnormalities in ß-adrenergic receptor subtype expression or in the G-protein complex. However, future studies that more carefully examine specific cellular and molecular changes in the ß-adrenergic system with concomitant ACE inhibition and the progression of tachycardia-induced cardiomyopathy are necessary to directly address this issue.

While myocyte contractile function was improved with concomitant ACE inhibition during long-term rapid pacing, significant abnormalities in myocyte function were observed compared with control myocytes. First, in the present study, myofibrillar disarray was observed within the myocytes after chronic tachycardia, and ACE inhibition did not appear to improve this defect in cytoarchitecture. Moreover, when expressed in terms of wet weight of LV myocardium, ACE inhibition with chronic tachycardia caused a reduction in MHC content. Next, it was demonstrated that chronic tachycardia is associated with abnormalities in sarcolemmal receptor systems such as the Na+,K+-ATPase system.10 20 Finally, downregulation of Ca2+ transport systems within the sarcoplasmic reticulum, alterations in Ca2+ homeostasis, and diminished myocyte responsiveness to Ca2+ all have been reported to occur with tachycardia-induced cardiomyopathy.17 21 Thus, potential mechanisms for the persistent abnormalities in myocyte function associated with ACE inhibition and chronic tachycardia include abnormalities in myocyte composition, changes in sarcolemmal function, and alterations in Ca2+ homeostasis.

The present study also provides evidence to suggest that the mechanism for the protective effects of ACE inhibition in this model of dilated cardiomyopathy was not due to prevention of the activation of the endocrine-humoral renin-angiotensin system or systemic hemodynamic effects. First, chronic tachycardia was not associated with increased plasma renin activity. This was probably due to stable hemodynamics in this model of cardiomyopathy. This is consistent with past experimental reports in which a significant rise in plasma renin activity was not observed with chronic tachycardia until severe hemodynamic compromise or end-organ perfusion occurred.7 16 24 Thus, it is unlikely that the protective effects of ACE inhibition in this model of tachycardia-induced cardiomyopathy were due to a reduction in circulating plasma angiotensin II concentrations. However, it must be recognized that the present study did not directly measure plasma angiotensin II levels or ACE activity with long-term rapid pacing. Second, mean arterial pressure, while reduced with concomitant ACE inhibition, was similar compared with that in dogs with tachycardia-induced cardiomyopathy. Thus, it is unlikely that prevention of LV dilation and improved indexes of myocyte contractile function with ACE inhibition were due simply to differences in systemic hemodynamic effects.

The potential contributory mechanisms for the improved LV and myocyte function with ACE inhibition during chronic tachycardia include changes in the intrinsic myocardial renin-angiotensin system and modulation of alternative enzymatic pathways. In vitro binding studies, steady-state mRNA measurements, and in situ hybridization studies provided evidence for a local renin-angiotensin system within the myocardium.48 49 Furthermore, increased myocardial ACE mRNA levels and activity were reported with tachycardia-induced heart failure in rats.9 In the present study, ACE inhibition during chronic tachycardia may have prevented the deleterious effects of endogenous production of angiotensin II within the myocardium. ACE inhibition was achieved through the use of the nonsulfhydryl compound fosinopril. This particular ACE inhibitor is converted to the biologically active fosinoprilic acid after oral administration.50 It was demonstrated previously that fosinoprilic acid penetrates the myocardium and suppresses myocardial ACE activity to a greater degree than other ACE inhibitors.51 These findings present additional evidence to suggest that the effects on LV geometry and structure of long-term rapid pacing and concomitant ACE inhibition observed in the present study were due to myocardial ACE inhibition. However, future studies that directly measure myocardial ACE activity in the presence and absence of ACE inhibition in this model of cardiomyopathic disease are necessary to directly address this issue. Significant evidence suggests that kallikrein-kinin proteolytic cascade systems exist within the myocardium.52 53 54 55 Bradykinin, a nonapeptide produced by the kallikrein cascade, has been implicated to play a direct role in myocardial remodeling and functional recovery from myocardial ischemia.53 54 55 Moreover, ACE inhibition appears to prevent the rapid degradation of bradykinin and thereby potentiate the beneficial effects of this peptide in the setting of myocardial ischemia.55 Thus, a contributory mechanism for the beneficial effects of concomitant ACE inhibition observed in the present study may be due to enhanced bradykinin levels within the myocardium. While concomitant ACE inhibition improved LV geometry and myocyte function with chronic tachycardia, it did not completely prevent the development of LV dilation and contractile dysfunction. Past studies demonstrated that alternative enzymatic pathways exist for the production of angiotensin II within the myocardium.56 57 58 Specifically, a serine proteinase chymase has been demonstrated in human myocardium that can hydrolyze angiotensin I to angiotensin II.56 57 58 Accordingly, ACE inhibition may not totally prevent myocardial angiotensin II production owing to these alternative pathways. Thus, in the present study, myocardial angiotensin II production may have occurred despite concomitant ACE inhibition with chronic tachycardia. Future studies that use specific bradykinin and angiotensin II receptor antagonists in this model of tachycardia-induced cardiomyopathy will be necessary to elucidate the interdependence and functional significance of the myocardial angiotensin II and bradykinin forming pathways with the progression of cardiomyopathic disease.

Consistent with a number of past reports, tachycardia-induced cardiomyopathy caused LV dilation with no change in LV mass.7 9 18 19 20 21 22 23 25 Chronic tachycardia and concomitant ACE inhibition caused a reduction in LV volumes compared with values from dogs undergoing rapid pacing only, and LV mass was reduced from control values. Results from the present study suggest that the cellular basis for these changes in LV geometry and mass with ACE inhibition were a reduction in myocyte length, a decreased cross-sectional area, and a small decline in LV myocardial protein content. A contributory factor for neuroendocrine modulation of myocardial growth is the production of angiotensin II.59 Furthermore, it has been clearly established that ACE inhibition will reduce the degree of LV hypertrophy with a chronic pressure overload.60 Thus, the reduction in LV mass and myocyte size with long-term ACE inhibition observed in the present study may be due to removal of the trophic effects of angiotensin II. To more carefully examine the structural determinants for the improved myocyte contractile function with concomitant ACE inhibition and rapid pacing, myofibril protein structure and content were examined. In the present study, long-term rapid pacing in dogs did not significantly change myocyte myofibril content. This is in contrast to findings previously reported from this laboratory in which a reduction in myofibril content was observed in pigs with pacing-induced cardiomyopathy.19 21 Probable explanations for these disparate findings include the degree of LV dysfunction and neurohormonal activation. Nevertheless, the findings from the present study suggest that myofibril degeneration is not a prerequisite for the development of severe LV and myocyte dysfunction with chronic tachycardia. In the present study, MHC content was not significantly reduced with long-term rapid pacing. This finding provides further evidence to suggest that the basic abnormality underlying the myocyte contractile dysfunction in this model of tachycardia-induced cardiomyopathy is probably not due to an absolute loss of myosin. However, inspection of electron micrographs revealed qualitative changes in myofibril orientation and alignment with long-term rapid pacing. Thus, conformational changes in the contractile apparatus or alterations in the stoichiometric relation between myosin and other contractile proteins cannot be ruled out.

Biochemical and morphometric examinations of LV myocardium after chronic tachycardia with ACE inhibition revealed an increased collagen weave that surrounded individual myocytes. This laboratory and others have demonstrated a disruption in the fibrillar collagen weave within the LV myocardium after the development of tachycardia-induced cardiomyopathy.22 36 41 The increased collagen weave within the LV myocardium with ACE inhibition and rapid pacing may have improved interstitial support and thereby reduced potential stress and deformation on the myocyte. The findings from the present study provide evidence to suggest that changes in the collagen matrix play a contributory role in the progressive LV dilation that occurs with long-term tachycardia. The underlying mechanisms for the changes in collagen content and structure with chronic rapid pacing and concomitant ACE inhibition include alterations in collagen synthesis and degradation. It was demonstrated that the expression and synthesis of fibrillar collagens by the fibroblast are significantly influenced by neurohormonal changes.61 In the present study, concomitant ACE inhibition with rapid pacing significantly attenuated indexes of neurohormonal activation. Thus, ACE inhibition in this model of cardiomyopathic disease may have influenced fibroblast synthetic capacity. Collagen degradation occurs primarily through the activation of a number of matrix metalloproteinases.62 63 Of these metalloproteinases, interstitial collagenase (MMP-1), 72- to 92-kD gelatinase, and stromelysin probably play the most significant role in myocardial collagen degradative processes.62 63 Expression of metalloproteinases by fibroblasts can be upregulated quickly by neurohormones and cytokines. In addition, it has been demonstrated that the ACE inhibitor captopril significantly reduced the activity of matrix metalloproteases in vitro.64 Thus, in the present study, the increased myocardial collagen content and preservation of collagen structure with ACE inhibition may have been due to modulation of metalloproteinase activity.

To the best of our knowledge, this is the first study to examine the direct effects of long-term ACE inhibition on LV and myocyte structure and function with the development of dilated cardiomyopathy. Brands et al13 demonstrated a significant improvement in cardiac output after 7 days of rapid ventricular pacing in dogs with ACE inhibition. However, serial changes in LV function and geometry with longer durations of rapid pacing and ACE inhibition were not addressed in this past report. In a recent study, Sabbah et al34 demonstrated that ACE inhibition in dogs with LV dysfunction caused by repetitive microembolization attenuated the progressive LV dilation and improved LV ejection fraction in this model of cardiomyopathic disease. While few studies have serially examined changes in LV function with ACE inhibition in models of cardiomyopathic disease, clinical studies have demonstrated clear and beneficial effects of long-term ACE inhibition in patients with reduced LV ejection fraction.2 3 4 Results from the present study suggest that the improved LV function in past experimental studies and the improved survival observed in clinical reports are due to direct and beneficial effects of ACE inhibition on LV geometry and myocyte contractile function.

Study Limitations
This study has several limitations that must be recognized. First, while this study demonstrated that concomitant ACE inhibition ameliorated the LV dilation and myocyte contractile dysfunction with chronic tachycardia, the underlying contributory mechanisms responsible for these effects remain unresolved. A second limitation is that 4 weeks of rapid pacing in dogs did not cause a significant increase in plasma renin activity in the untreated dogs. This is in contrast to past reports7 14 16 24 and suggests that significant activation of systemic neurohormonal systems such as the renin-angiotensin system had not occurred. Thus, a future study examing the direct effects of ACE inhibition in this model of cardiomyopathic disease with more severe hemodynamic compromise with subsequent activation of the systemic renin-angiotensin system would be appropriate. In the present study, concomitant ACE inhibition with rapid pacing had direct effects on LV mass and composition. Specifically, ACE inhibition reduced LV mass compared with the control group and the group undergoing rapid pacing only. It has been well documented that long-term ACE inhibition can regress LV hypertrophy in the setting of pressure overload.60 However, several studies also demonstrated that long-term ACE inhibition in normal animals reduced LV mass.65 66 Thus, it remains unclear whether the reduction of LV mass observed in the present study was due to specific inhibition of myocardial ACE activity with the development of pacing-induced cardiomyopathic disease or to the general effects of long-term ACE inhibition. In light of the findings of the present study, a future study in which drug controls are included in the experimental design is necessary to address this issue. Finally, the present study examined LV and myocyte structure and function with long-term rapid pacing at only one point in time. Thus, serial changes in LV myocardial and myocyte structure and the effects of ACE inhibition in this model of cardiomyopathic disease were not addressed.

Conclusions
Consistent with past reports,7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 chronic tachycardia in dogs caused LV dilation and dysfunction. At the cellular level, chronic tachycardia caused depressed myocyte contractile function and blunted ß-adrenergic responsiveness. Concomitant ACE inhibition improved LV geometry and myocyte function with chronic tachycardia. Specifically, the degree of LV dilation was reduced and myocyte ß-adrenergic responsiveness was improved with chronic tachycardia and ACE inhibition. Contributory factors for this improvement in LV geometry and myocyte contractile function with ACE inhibition included increased extracellular support from the collagen matrix and a normalization of the ß-adrenergic receptor system. The results from the present study provide new evidence that long-term ACE inhibition during the progression of cardiomyopathic disease provided beneficial cellular and extracellular effects within the LV myocardium.


*    Acknowledgments
 
This work was supported by NIH grant R29-HL-45024 (Dr Spinale), a basic research grant from Bristol Myers Research Institute (Dr Spinale), the Thoracic Surgery Foundation for Research and Education (Dr Walker), and a Medical University of South Carolina postdoctoral research award (Drs Hird and Walker). Dr Walker is a Nina S. Braunwald Research Fellow. Dr Spinale is an Established Investigator of the American Heart Association.

Received November 7, 1994; revision received January 23, 1995; accepted January 23, 1995.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 
1. Manolio TA, Baughman KL, Rodeheffer R, Pearson TA, Bristow JD, Michels W, Abelman WH, Harlan WR. Prevalence and etiology of idiopathic dilated cardiomyopathy: summary of a National Heart, Lung, and Blood Institute Workshop. Am J Cardiol. 1992;69:1458-1466. [Medline] [Order article via Infotrieve]

2. Benedict CR, Weiner DH, Johnstone DE, Bourassa MG, Ghali JK, Nicklas J, Kirlin P, Greenberg B, Quinones MA, Yusuf S. Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the studies of left ventricular dysfunction (SOLVD) registry. J Am Coll Cardiol. 1993;22:146A-153A.

3. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandanavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435. [Abstract]

4. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302. [Abstract]

5. Pitt B. Use of converting enzyme inhibitors in patients with asymptomatic left ventricular dysfunction. J Am Coll Cardiol. 1993;22:158A-161A.

6. Poole-Wilson PA. Relation of pathophysiological mechanisms to outcome in heart failure. J Am Coll Cardiol. 1993;22:22A-29A.

7. Armstrong PW, Stopps TP, Ford SE, DeBold AJ. Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure. Circulation. 1986;74:1075-1084. [Abstract/Free Full Text]

8. Kiuchi K, Shannon RP, Komamura K, Cohen DJ, Bianchi C, Homcy CJ, Vatner SF, Vatner DE. Myocardial ß-adrenergic receptor function during the development of pacing induced heart failure. J Clin Invest. 1993;91:907-914.

9. Finckh M, Hellmann W, Ganten D, Furtwangler A, Allgeier J, Boltz M, Holtz J. Enhanced cardiac angiotensinogen gene expression and angiotensin converting enzyme activity in tachypacing induced heart failure in rats. Basic Res Cardiol. 1991;86:303-316. [Medline] [Order article via Infotrieve]

10. Kim CH, Fan THM, Kelly PF, Himura Y, Delehanty JM, Hang CL, Liang CS. Isoform specific regulation of myocardial Na+,K+-ATPase {alpha}-subunit in congestive heart failure: role of norepinephrine. Circulation. 1994;89:313-320. [Abstract/Free Full Text]

11. Moe GW, Grima EA, Howard RJ, Seth R, Armstrong PW. Left ventricular remodeling and disparate changes in contractility and relaxation during the development of and recovery from experimental heart failure. Cardiovasc Res. 1994;28:66-71. [Abstract/Free Full Text]

12. Margulies KB, Perrella MA, McKinley LJ, Burnett JC. Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure.J Clin Invest. 1991;88:1636-1642.

13. Brands MW, Galicia-Alonso M, Mizelle HL, Montani JP, Hildebrandt DA, Hall JE. Chronic angiotensin converting enzyme inhibition improves cardiac output and fluid balance during heart failure. Am J Physiol. 1993;264:R414-R422. [Abstract/Free Full Text]

14. Moe GW, Stopps TP, Angus C, Forster C, DeBold AJ, Armstrong PW. Alterations in serum sodium in relation to atrial natriuretic factor and other neuroendocrine variables in experimental pacing induced heart failure. J Am Coll Cardiol. 1989;13:173-179. [Abstract]

15. Redfield MM, Edwards BS, McGoon MD, Heublein DM, Aarhus LL, Burnett JC. Failure of atrial natriuretic factor to increase with volume expansion in acute and chronic congestive cardiac failure in the dog. Circulation. 1989;80:651-657. [Abstract/Free Full Text]

16. Riegger GA, Elsner D, Kromer EP, Daffner C. Atrial natriuretic peptide in congestive heart failure in the dog: plasma levels, cyclic guanosine monophosphate, ultrastructure of atrial myoendocrine cells, and hemodynamic, hormonal, and renal effects. Circulation. 1988;77:398-406.[Abstract/Free Full Text]

17. Cory CR, McCutcheon LJ, O'Grady M, Pang AW, Geiger JD, O'Brien PJ. Compensatory downregulation of myocardial Ca channel in SR from dogs with heart failure. Am J Physiol. 1993;264:H926-H937. [Abstract/Free Full Text]

18. Roth DA, Urasawa K, Helmer GA, Hammond HK. Downregulation of cardiac guanosine 5'-triphosphate binding proteins in right atrium and left ventricle in pacing induced congestive heart failure. J Clin Invest. 1993;91:939-949.

19. Spinale FG, Zellner JL, Tomita M, Crawford FA, Zile MR. Relationship between ventricular and myocyte remodeling with the development and regression of supraventricular tachycardia induced cardiomyopathy. Circ Res. 1991;69:1058-1067. [Abstract/Free Full Text]

20. Spinale FG, Clayton C, Tanaka R, Fulbright BM, Mukherjee R, Schulte BA, Crawford FA, Zile MR. Myocardial Na+,K+-ATPase in tachycardia induced cardiomyopathy. J Mol Cell Cardiol. 1992;24:277-294. [Medline] [Order article via Infotrieve]

21. Spinale FG, Fulbright BM, Mukherjee R, Tanaka R, Hu J, Crawford FA, Zile MR. Relationship between ventricular and myocyte function with tachycardia induced cardiomyopathy. Circ Res. 1992;71:174-187. [Abstract/Free Full Text]

22. Spinale FG, Tomita M, Zellner JL, Cook JC, Crawford FA, Zile MR. Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia. Am J Physiol. 1991;261(Heart Circ Physiol. 30):H308-H318.

23. Tanaka R, Fulbright BM, Mukherjee R, Burchell SA, Zile MR, Spinale FG. The cellular basis for the blunted response to ß-adrenergic stimulation in supraventricular tachycardia induced cardiomyopathy. J Mol Cell Cardiol. 1993;25:1215-1233. [Medline] [Order article via Infotrieve]

24. Travill CM, Williams TDM, Pate P, Song G, Chalmers J, Lightman SL, Sutton R, Noble MIM. Hemodynamic and neurohormonal response in heart failure produced by rapid ventricular pacing. Cardiovasc Res. 1992;26:783-790. [Abstract/Free Full Text]

25. Tomita M, Spinale FG, Crawford FA, Zile MR. Changes in left ventricular volume, mass, and function during development and regression of supraventricular tachycardia-induced cardiomyopathy: disparity between recovery of systolic vs diastolic function. Circulation. 1991;83:635-644. [Abstract/Free Full Text]

26. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Jamieson S, Stinson EB. ß1 and ß2 Adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective ß1-receptor downregulation in heart failure. Circ Res. 1986;59:297-309. [Abstract/Free Full Text]

27. Marshall SA, Levine RA, Weyman AE. Echocardiography in cardiac research. In: Fozzard HA, Haber E, Jennings RB, Katz AM, Morgan HE, eds. The Heart and Cardiovascular System. 2nd ed. New York, NY: Raven Press, Ltd; 1992:745-837.

28. Goldstein DS, Feuerstein G, Izzo HL, Kopin IJ, Keiser H. Validity and reliability of liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epinephrine in man. Life Sci (England). 1981;28:467-475.

29. Laboratory Methods in Histotechnology. In: Prophet EB, Mills B, Arrington JB, Sobin LH, eds. Laboratory Methods in Histotechnology. Washington, DC: Armed Forces Institute of Pathology; 1992:137-140.

30. Esser KA, Boluyt MO, White TP. Separation of cardiac myosin heavy chains by gradient SDS-PAGE. Am J Physiol. 1988;255:H659-H663. [Abstract/Free Full Text]

31. Stegemann H, Stalder K. Determination of hydroxyproline. Clin Chim Acta. 1967;18:267-273.[Medline] [Order article via Infotrieve]

32. Belardinelli L, Isenberg G. Actions of adenosine and isoproterenol on isolated mammalian ventricular myocytes. Circ Res. 1983;53:287-297. [Abstract/Free Full Text]

33. Steel RGD, Torrie JH. Principles and Procedures of Statistics: A Biometrical Approach. 2nd ed. New York, NY: McGraw-Hill Publishing Co; 1980;137-238.

34. Sabbah HN, Shimoyama H, Kono T, Gupta RC, Sharov VG, Scicli G, Levine TB, Goldstein S. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation. 1994;89:2852-2859. [Abstract/Free Full Text]

35. Bienvenu JG, Drolet R. A quantitative study of cardiac ventricular mass in dogs. Can J Vet Res. 1991;55:305-309. [Medline] [Order article via Infotrieve]

36. Weber KT, Pick RP, Silver MA, Moe GW, Janicki JS, Zucker IH, Armstrong PW. Fibrillar collagen and remodeling of dilated canine left ventricle. Circulation. 1990;82:1387-1401. [Abstract/Free Full Text]

37. Tsutsui H, Urabe Y, Mann DL, Tagawa H, Carabello BA, Cooper G, Zile MR. Effects of chronic mitral regurgitation on diastolic function in isolated cardiocytes. Circ Res. 1993;72:1110-1123. [Abstract/Free Full Text]

38. Weber KT. Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol. 1989;13:1637-1652. [Abstract]

39. Robinson TF, Cohen-Gould L, Factor SM. Skeletal framework of mammalian heart muscle: arrangement of inter- and pericellular connective tissue structures. Lab Invest. 1983;49:482-498. [Medline] [Order article via Infotrieve]

40. Caulfield JB, Borg TK. The collagen network of the heart. Lab Invest. 1979;40:364-372. [Medline] [Order article via Infotrieve]

41. Bishop SP, Powell PC, Brissie N, Komamura K, Shannon RP. Myocardial cellular remodeling in canine pacing induced heart failure. Circulation. 1992;86(suppl I):754. Abstract.

42. Janicki JS, Matsubara BB. Myocardial collagen and left ventricular diastolic dysfunction. In: Gaasch WH, LeWinter MM, eds. Left Ventricular Diastolic Dysfunction and Heart Failure. Philadelphia, Pa: Lea & Febiger; 1994:125-140.

43. Mukherjee D, Sen S. Alteration of cardiac collagen phenotypes in hypertensive hypertrophy: role of blood pressure. J Mol Cell Cardiol. 1993;25:185-196. [Medline] [Order article via Infotrieve]

44. Spinale FG, Tempel GE, Mukherjee R, Eble DM, Brown R, Vacchiano C, Zile MR. Cellular and molecular changes in the ß-adrenergic receptor system with supraventricular tachycardia induced cardiomyopathy. Cardiovasc Res. 1994;28:1243-1250. [Abstract/Free Full Text]

45. Eschenhagen T, Mende U, Nose M, Schmitz W, Scholz H, Haverich A, Hirt S, Doring V, Kalmar P, Hoppner W, Seitz HJ. Increased messenger RNA level of the inhibitory G protein {alpha} subunit G{alpha}i-2 in human end stage heart failure. Circ Res. 1992;70:688-696. [Abstract/Free Full Text]

46. Bristow MR, Minobe W, Rasmussen R, Larrabee P, Skert L, Klein JW, Anderson FL, Murray J, Mestroni L, Karwande SV, Fowler M, Ginsburg R. ß-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest. 1992;89:803-815.

47. Maisel AS, Phillips C, Michel MC, Ziegler MG, Carter SM. Regulation of cardiac ß-adrenergic receptors by captopril: implications for congestive heart failure. Circulation. 1989;80:669-675. [Abstract/Free Full Text]

48. Baker KM, Booz GW, Dostal DE. Cardiac actions of angiotensin II: role of an intracardiac renin-angiotensin system. Annu Rev Physiol. 1992;54:227-241. [Medline] [Order article via Infotrieve]

49. Hirsch AT, Talsness CE, Schunkert H, Paul M, Dzau VJ. Tissue specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res. 1991;69:475-482. [Abstract/Free Full Text]

50. Zusman RM. Angiotensin converting enzyme inhibitors: more different than alike? Focus on cardiac performance. Am J Cardiol. 1993;72:25H-36H. [Medline] [Order article via Infotrieve]

51. Grover GJ, Sleph PG, Dzwonczyk S, Wang P, Fung W, Tobias D, Cushman DW. Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: relationship between cardiac ACE inhibition and cardioprotection. J Pharmacol Exp Ther. 1991;257:919-929. [Abstract/Free Full Text]

52. Nolly H, Carbini LA, Scicli G, Carretero OA, Scili AG. A local kallikrein-kinin system is present in rat hearts. Hypertension. 1994;23:919-923.[Abstract/Free Full Text]

53. Gavras H. Angiotensin converting enzyme inhibition and the heart. Hypertension. 1994;23:813-818. [Free Full Text]

54. Gohlke P, Linz W, Scholkens BA, Kuwer I, Bartenbach S, Schnell A, Unger T. Angiotensin converting enzyme inhibition improves cardiac function: role of bradykinin. Hypertension. 1994;23:411-418. [Abstract/Free Full Text]

55. Weber KT, Sun Y, Guarda E. Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension. 1994;23:869-877. [Abstract/Free Full Text]

56. Ehring T, Baumgart D, Krajcar M, Hummelgen M, Kompa S, Heusch G. Attenuation of myocardial stunning by the ACE inhibitor ramiprilat through a signal cascade of bradykinin and prostaglandins but not nitric oxide. Circulation. 1994;90:1368-1385. [Abstract/Free Full Text]

57. Urata H, Boehm KD, Philip A, Kinoshita A, Gabrovsek J, Bumpus FM, Husain A. Cellular localization and regional distribution of an angiotensin II forming chymase in the heart. J Clin Invest. 1993;91:1269-1281.

58. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II forming pathways in normal and failing human hearts. Circ Res. 1990;66:883-890. [Abstract/Free Full Text]

59. Morgan HE, Baker KM. Cardiac hypertrophy: mechanical, neural, and endocrine dependence. Circulation. 1991;83:13-25. [Free Full Text]

60. Lorell BH. Diastolic dysfunction in pressure-overload hypertrophy and its modification by angiotensin II: current concepts. Basic Res Cardiol. 1992;87:163-172.

61. Weber KT, Anversa P, Armstrong PW, Brilla CG, Burnett JC, Cruickshank JM, Devereux RB, Giles TD, Korsgaard N, Leier CV, Mendelsohn FAO, Motz WH, Mulvany MJ, Strauer BE. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol. 1992;20:3-16. [Abstract]

62. Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991;5:2145-2154. [Abstract]

63. Werb Z, Alexander CM. Proteinases and matrix degradation. In: Kelly WH, Harris ED, Ruddy S, Sledge CB, eds. Text- book of Rheumatology. Philadelphia, Pa: WB Saunders; 1993: 248-268.

64. Sorbi D, Fadly M, Hicks R, Alexander S, Arbeit L. Captopril inhibits the 72 kDa and 92 kDa matrix metalloproteinases. Kidney Int. 1993;44:1266-1272. [Medline] [Order article via Infotrieve]

65. Mooser V, Casley D, Trinder D, Paxton DL, Johnston CI. Reduction in left ventricular mass in normotensive and spontaneously hypertensive rats given enalapril. Clin Exp Pharmacol Physiol. 1991;18:341-344. [Medline] [Order article via Infotrieve]

66. Limas C, Westrum B, Limas CJ. Comparative effects of hydralazine and captopril on the cardiovascular changes in spontaneously hypertensive rats. Am J Pathol. 1984;117:360-371.[Abstract]




This article has been cited by other articles:


Home page
Circ Heart FailHome page
J. A. Dixon and F. G. Spinale
Large Animal Models of Heart Failure: A Critical Link in the Translation of Basic Science to Clinical Practice
Circ Heart Fail, May 1, 2009; 2(3): 262 - 271.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
Z.-S. Zhang, H.-J. Cheng, K. Onishi, N. Ohte, T. Wannenburg, and C.-P. Cheng
Enhanced Inhibition of L-type Ca2+ Current by {beta}3-Adrenergic Stimulation in Failing Rat Heart
J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1203 - 1211.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. Poelzing and D. S. Rosenbaum
Altered connexin43 expression produces arrhythmia substrate in heart failure
Am J Physiol Heart Circ Physiol, October 1, 2004; 287(4): H1762 - H1770.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
W. M. Yarbrough, R. Mukherjee, G. P. Escobar, J. T. Mingoia, J. A. Sample, J. W. Hendrick, K. B. Dowdy, J. E. McLean, A. S. Lowry, T. P. O'Neill, et al.
Selective Targeting and Timing of Matrix Metalloproteinase Inhibition in Post-Myocardial Infarction Remodeling
Circulation, October 7, 2003; 108(14): 1753 - 1759.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. C. Borges, J. A. Silva Jr., M. A. Gomes, E. S. L. Lomez, K. M. Leite, R. C. Araujo, M. Bader, J. B. Pesquero, and J. L. Pesquero
Tonin in rat heart with experimental hypertrophy
Am J Physiol Heart Circ Physiol, June 1, 2003; 284(6): H2263 - H2268.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. Mishra, H. N. Sabbah, J. C. Jain, and R. C. Gupta
Reduced Ca2+-calmodulin-dependent protein kinase activity and expression in LV myocardium of dogs with heart failure
Am J Physiol Heart Circ Physiol, March 1, 2003; 284(3): H876 - H883.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
M. M. Multani, R. S. Krombach, A. T. Goldberg, M. K. King, J. W. Hendrick, J. A. Sample, S. C. Baicu, C. Joffs, M. deGasparo, and F. G. Spinale
Myocardial Bradykinin Following Acute Angiotensin-Converting Enzyme Inhibition, AT1 Receptor Blockade, or Combined Inhibition in Congestive Heart Failure
Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2001; 6(4): 369 - 376.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
M. E. Khalil, A. W. Basher, E. J. Brown Jr, and I. A. Alhaddad
A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients
J. Am. Coll. Cardiol., June 1, 2001; 37(7): 1757 - 1764.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C.-P. Cheng, T. Ukai, K. Onishi, N. Ohte, M. Suzuki, Z.-S. Zhang, H.-J. Cheng, H. Tachibana, A. Igawa, and W. C. Little
The role of ANG II and endothelin-1 in exercise-induced diastolic dysfunction in heart failure
Am J Physiol Heart Circ Physiol, April 1, 2001; 280(4): H1853 - H1860.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. J. Woodiwiss, O. J. Tsotetsi, S. Sprott, E. J. Lancaster, T. Mela, E. S. Chung, T. E. Meyer, and G. R. Norton
Reduction in Myocardial Collagen Cross-Linking Parallels Left Ventricular Dilatation in Rat Models of Systolic Chamber Dysfunction
Circulation, January 2, 2001; 103(1): 155 - 160.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. Y Heinke, M. Yao, D. Chang, R. Einstein, and C. G dos Remedios
Apoptosis of ventricular and atrial myocytes from pacing-induced canine heart failure
Cardiovasc Res, January 1, 2001; 49(1): 127 - 134.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
B. D. Hoit and M. Gabel
Influence of left ventricular dysfunction on the role of atrial contraction: An echocardiographic-hemodynamic study in dogs
J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1713 - 1719.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. J. Clair, M. K. King, A. T. Goldberg, J. W. Hendrick, R. Nisato, D. M. Gay, A. E. Morrison, J. H. McElmurray III, R. S. Krombach, B. R. Bond, et al.
Selective Vasopressin, Angiotensin II, or Dual Receptor Blockade with Developing Congestive Heart Failure
J. Pharmacol. Exp. Ther., June 1, 2000; 293(3): 852 - 860.
[Abstract] [Full Text]


Home page
Cardiovasc ResHome page
F. G Spinale, M. L Coker, B. R Bond, and J. L Zellner
Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target
Cardiovasc Res, May 1, 2000; 46(2): 225 - 238.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
R. S. Krombach, J. H. McElmuray, D. M. Gay, M. J. Clair, R. Mukherjee, A. T. Goldberg, S. C. Baicu, and F. G. Spinale
Bradykinin Degradation and Relation to Myocyte Contractility
Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(4): 291 - 299.
[Abstract] [PDF]


Home page
CirculationHome page
W. V. Houck, L. C. Pan, S. B. Kribbs, M. J. Clair, G. M. McDaniel, R. S. Krombach, W. M. Merritt, C. Pirie, J. P. Iannini, R. Mukherjee, et al.
Effects of Growth Hormone Supplementation on Left Ventricular Morphology and Myocyte Function With the Development of Congestive Heart Failure
Circulation, November 9, 1999; 100(19): 2003 - 2009.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. H. McElmurray III, R. Mukherjee, R. B. New, A. C. Sampson, M. K. King, J. W. Hendrick, A. Goldberg, T. J. Peterson, H. Hallak, M. R. Zile, et al.
Angiotensin-Converting Enzyme and Matrix Metalloproteinase Inhibition with Developing Heart Failure: Comparative Effects on Left Ventricular Function and Geometry
J. Pharmacol. Exp. Ther., November 1, 1999; 291(2): 799 - 811.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
H. Kawai, T.-H. M. Fan, E. Dong, R. A. Siddiqui, A. Yatani, S. Y. Stevens, and C.-S. Liang
ACE inhibition improves cardiac NE uptake and attenuates sympathetic nerve terminal abnormalities in heart failure
Am J Physiol Heart Circ Physiol, October 1, 1999; 277(4): H1609 - H1617.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
Y. Murakami, Y. Zhang, Y. K. Cho, A. M. Mansoor, J. K. Chung, C. Chu, G. Francis, K. Ugurbil, R. J. Bache, A. H. L. From, et al.
Myocardial Oxygenation During High Work States in Hearts With Postinfarction Remodeling
Circulation, February 23, 1999; 99(7): 942 - 948.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. Saad, R. Mukherjee, P. B. Thomas, J. P. Iannini, C. G. Basler, L. Hebbar, S.-J. O, S. Moreland, M. L. Webb, J. R. Powell, et al.
The effects of endothelin-A receptor blockade during the progression of pacing-induced congestive heart failure
J. Am. Coll. Cardiol., November 15, 1998; 32(6): 1779 - 1786.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
F. G. Spinale, R. Mukherjee, R. S. Krombach, M. J. Clair, J. W. Hendrick, W. V. Houck, L. Hebbar, S. B. Kribbs, J. L. Zellner, and M. G. Dodd
Chronic Amlodipine Treatment During the Development of Heart Failure
Circulation, October 20, 1998; 98(16): 1666 - 1674.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
H. F. Clemo, B. S. Stambler, and C. M. Baumgarten
Persistent Activation of a Swelling-Activated Cation Current in Ventricular Myocytes From Dogs With Tachycardia-Induced Congestive Heart Failure
Circ. Res., July 27, 1998; 83(2): 147 - 157.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
G. Hasenfuss
Animal models of human cardiovascular disease, heart failure and hypertrophy
Cardiovasc Res, July 1, 1998; 39(1): 60 - 76.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
R.S. Krombach, M. J Clair, J. W Hendrick, W. V Houck, J. L Zellner, S. B Kribbs, S. Whitebread, R. Mukherjee, M. de Gasparo, and F. G Spinale
Angiotensin converting enzyme inhibition, AT1 receptor inhibition, and combination therapy with pacing induced heart failure: effects on left ventricular performance and regional blood flow patterns
Cardiovasc Res, June 1, 1998; 38(3): 631 - 645.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
F. G. Spinale, M. L. Coker, C. V. Thomas, J. D. Walker, R. Mukherjee, and L. Hebbar
Time-Dependent Changes in Matrix Metalloproteinase Activity and Expression During the Progression of Congestive Heart Failure : Relation to Ventricular and Myocyte Function
Circ. Res., March 9, 1998; 82(4): 482 - 495.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
H. Senzaki, Y. A. Gluzband, P. H. Pak, M. T. Crow, J. S. Janicki, and D. A. Kass
Synergistic Exacerbation of Diastolic Stiffness From Short-term Tachycardia–Induced Cardiodepression and Angiotensin II
Circ. Res., March 9, 1998; 82(4): 503 - 512.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
S. B. Kribbs, W. M. Merritt, M. J. Clair, R. S. Krombach, W. V. Houck, M. G. Dodd, R. Mukherjee, and F. G. Spinale
Amlodipine Monotherapy, Angiotensin-Converting Enzyme Inhibition, and Combination Therapy With Pacing-Induced Heart Failure
Hypertension, March 1, 1998; 31(3): 755 - 765.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
F. G. Spinale, H. H. Holzgrefe, R. Mukherjee, M. L. Webb, R. B. Hird, M. J. Cavallo, J. R. Powell, and W. H. Koster
Angiotensin-Converting Enzyme Inhibition and Angiotensin II Subtype-1 Receptor Blockade during the Progression of Left Ventricular Dysfunction: Differential Effects on Myocyte Contractile Processes
J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1082 - 1094.
[Abstract] [Full Text]


Home page
HypertensionHome page
M. Takemoto, K. Egashira, H. Tomita, M. Usui, H. Okamoto, A. Kitabatake, H. Shimokawa, K. Sueishi, and A. Takeshita
Chronic Angiotensin-Converting Enzyme Inhibition and Angiotensin II Type 1 Receptor Blockade : Effects on Cardiovascular Remodeling in Rats Induced by the Long-term Blockade of Nitric Oxide Synthesis
Hypertension, December 1, 1997; 30(6): 1621 - 1627.
[Abstract] [Full Text]


Home page
CirculationHome page
F. G. Spinale, M. de Gasparo, S. Whitebread, L. Hebbar, M. J. Clair, D. M. Melton, R. S. Krombach, R. Mukherjee, J. P. Iannini, and S.-J. O
Modulation of the Renin-Angiotensin Pathway Through Enzyme Inhibition and Specific Receptor Blockade in Pacing-Induced Heart Failure : I. Effects on Left Ventricular Performance and Neurohormonal Systems
Circulation, October 7, 1997; 96(7): 2385 - 2396.
[Abstract] [Full Text]


Home page
CirculationHome page
F. G. Spinale, R. Mukherjee, J. P. Iannini, S. Whitebread, L. Hebbar, M. J. Clair, D. M. Melton, M. H. Cox, P. B. Thomas, and P. B. Marc de Gasparo
Modulation of the Renin-Angiotensin Pathway Through Enzyme Inhibition and Specific Receptor Blockade in Pacing-Induced Heart Failure : II. Effects on Myocyte Contractile Processes
Circulation, October 7, 1997; 96(7): 2397 - 2406.
[Abstract] [Full Text]


Home page
Cardiovasc ResHome page
R. P. Shannon, S. Friedrich, M. Mathier, and D. R. Knight
Effects of renin inhibition compared to angiotensin converting enzyme inhibition in conscious dogs with pacing-induced heart failure
Cardiovasc Res, June 1, 1997; 34(3): 464 - 472.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
F. G. Spinale, J. D. Walker, R. Mukherjee, J. P. Iannini, A. T. Keever, and K. P. Gallagher
Concomitant Endothelin Receptor Subtype-A Blockade During the Progression of Pacing-Induced Congestive Heart Failure in Rabbits : Beneficial Effects on Left Ventricular and Myocyte Function
Circulation, April 1, 1997; 95(7): 1918 - 1929.
[Abstract] [Full Text]


Home page
CirculationHome page
E. O. Weinberg, M. A. Lee, M. Weigner, K. Lindpaintner, S. P. Bishop, C. R. Benedict, K. K. L. Ho, P. S. Douglas, E. Chafizadeh, and B. H. Lorell
Angiotensin AT1 Receptor Inhibition : Effects on Hypertrophic Remodeling and ACE Expression in Rats With Pressure-Overload Hypertrophy due to Ascending Aortic Stenosis
Circulation, March 18, 1997; 95(6): 1592 - 1600.
[Abstract] [Full Text]


Home page
CirculationHome page
E. J. Eichhorn and M. R. Bristow
Medical Therapy Can Improve the Biological Properties of the Chronically Failing Heart: A New Era in the Treatment of Heart Failure
Circulation, November 1, 1996; 94(9): 2285 - 2296.
[Abstract] [Full Text]


Home page
Circ. Res.Home page
C.-P. Cheng, M. Suzuki, N. Ohte, M. Ohno, Z.-M. Wang, and W. C. Little
Altered Ventricular and Myocyte Response to Angiotensin II in Pacing-Induced Heart Failure
Circ. Res., May 1, 1996; 78(5): 880 - 892.
[Abstract] [Full Text]


This Article
Right arrow Abstract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spinale, F. G.
Right arrow Articles by Koster, W. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spinale, F. G.
Right arrow Articles by Koster, W. H.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Cardiomyopathy